Axsome Therapeutics, Inc.
AXSM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$145.04
KIRA · Stoqly’s AI analyst, in plain words
- Axsome Therapeutics, Inc. had $638M of revenue in fiscal 2025, up 65.5% on the year before.
- Its operating margin was −26.1%, up 46.6 pts: of every 100 in sales, about −26 is left after running the business.
- Axsome Therapeutics, Inc. lost $183M in fiscal 2025.
- Free cash flow was −$93.9M in fiscal 2025, −14.7% of revenue.
- Axsome Therapeutics, Inc. has $128M more cash than debt.
Market cap
$7.5B
P/E
—
Revenue
$638M
Net income
−$183M
Free cash flow
−$93.9M
Operating margin
−26.1%
Axsome Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+65.5%
Yes. Sales grew 65.5% last year.
Does it make a profit?
−28.7%
No. It lost money last year.
Does profit turn into cash?
−14.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Axsome Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- Axsome Therapeutics, Inc.
- CIK
- 0001579428
Axsome Therapeutics, Inc. · AXSM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $271M | $386M | $638M |
| Revenue growth | — | — | — | 42.5% | 65.5% |
| Operating margin | — | — | −85.7% | −72.7% | −26.1% |
| Net income | −$130M | −$187M | −$239M | −$287M | −$183M |
| Net margin | — | — | −88.4% | −74.5% | −28.7% |
| Diluted EPS | −$3.47 | −$4.60 | −$5.27 | −$5.99 | −$3.68 |
| Cash | |||||
| Cash from operations | −$108M | −$117M | −$145M | −$128M | −$93.4M |
| Capital expenditure | $0.3M | $0.7M | $0.6M | $0.3M | $0.5M |
| Free cash flow | −$109M | −$117M | −$146M | −$129M | −$93.9M |
| FCF margin | — | — | −53.8% | −33.4% | −14.7% |
| Share count change | 1.1% | 8.1% | 11.7% | 5.5% | 3.8% |
| Debt and strength | |||||
| Cash and short-term investments | $86.5M | $201M | $386M | $315M | $323M |
| Debt incl. finance leases | $49.1M | $94.3M | $178M | $185M | $195M |
| Shareholders' equity | $15.6M | $110M | $191M | $57.0M | $88.3M |
| Current ratio | 3.8x | 2.5x | 3.6x | 2.1x | 1.6x |
| Returns and quality | |||||
| Return on capital | — | −4,777.7% | — | — | — |
| Return on equity | −201.5% | −299.0% | −159.2% | −231.6% | −252.1% |
| Return on tangible equity | −834.3% | −472.7% | −190.4% | — | −512.6% |
| Piotroski F-score | 1 | 3 | 4 | 2 | 4 |
| Altman Z'' | −19.8 | −6.0 | −2.7 | −6.7 | −5.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$134M
8 insiders
Of sales under plans
100%
$134M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Axsome Therapeutics, Inc. · AXSM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $145.04 a share, the company is worth $7.5B.
Source: SEC EDGAR XBRL filings (CIK 0001579428). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.